ALCAM has also been evaluated as a prognostic biomarker in a variety of cancers due to its overexpression in patients with breast [32, 34], ovarian [33], pancreatic [76], and non-small-cell lung cancers [77]. This evidence concerns the gene ALCAM and non-small cell lung carcinoma.